The IDM - a cross-faculty, multidisciplinary postgraduate health research institute
Based on the UCT Faculty of Health Sciences campus in a 7,100 sqm state-of-the-art facility, we operate in the fields of infectious diseases and molecular medicine.
Clinical research relevant to the needs of Africa's people
The IDM influences health policy and practice by translating our scientific discoveries and applying them in various communities; community relationships and trust are critical.
Capacity building in the IDM
The largest research entity at UCT, the IDM is a national leader in research and health sciences human capital development.
IDM driving world class research
We conduct research at the laboratory-clinic-community interface by engaging a wide range of scientific and clinical disciplines; with 62 consortia linking us with 183 institutions in 22 African countries and 24 countries beyond.
University accredited research institute - Tackling diseases of importance in Africa - Developing people - Impacting health policy and practice
The recent acquisition of a porfolio of key life sciences patents, promises to push cancer biotechnology research at the University of Cape Town (UCT) to new heights under the leadership of Professor Stefan Bath.
CIDRI-Africa clinician-scientist PhD fellows Elsa du Bruyn and Ashley Jacobs were recently awarded further support for their research by the Harry Crossley Foundation. Both will be researching aspects of tuberculosis (TB) infection in the context of HIV infection.
Professor Gary Maartens is both head of clinical pharmacology at the University of Cape Town (UCT) and a chief specialist physician at Groote Schuur Hospital. Earlier this year, South Africa’s National Research Foundation (NRF) recognised his contribution to the field by awarding him an A rating.
A breakthrough study conducted by Professor Keertan Dheda and Dr Michele Tomasicchio, at the University of Cape Town’s (UCT) Centre for Lung Infection and Immunity, has revealed that one of South Africa’s most commonly-used injectable contraceptives could potentially increase women’s chances of contracting tuberculosis (TB).